Minnesota Medicaid (Medical Assistance / MHCP) GLP-1 Coverage (2026): Pattern #20 — Affirmative Obesity-Indication Coverage With Dedicated "Weight Management Agents" PDL Class (Saxenda/Wegovy Preferred; Zepbound Non-Preferred) + Active Hostile Exclusion Legislation (HF4142 Laid Over 3/25/2026) + FFS-Direct No-PBM Architecture + Tirzepatide in Two PDL Classes

TL;DR — Minnesota Medical Assistance GLP-1 coverage status

Minnesota Medical Assistance (Medicaid) covers GLP-1 receptor agonists for the chronic-weight-management FDA indication with prior authorization. Coverage rests on three primary-source pillars verified as of May 10, 2026: (1) the Minnesota DHS Uniform PDL (effective January 1, 2025), which contains a dedicated “Weight Management Agents” therapeutic class listing Saxenda and Wegovy as Preferred and Zepbound as Non-preferred; (2) the DHS Anti-Obesity Medications PA criteria (revised March 2023), which sets BMI thresholds, lifestyle-documentation requirements, and a 5%-weight-loss renewal threshold; and (3) Minnesota Statutes § 256B.0625, subd. 13d, whose current six-item exclusion list does not include weight-loss drugs.

Active 2026 hostile legislation (HF4142 — Nadeau, Gander, Rehrauer): introduced March 9, 2026; laid over by the House Health Finance and Policy Committee on March 25, 2026 without a vote; no Senate companion. If enacted, HF4142 would add a new exclusion — “drugs or active pharmaceutical ingredients when used only for weight loss” — effective January 1, 2027, or upon federal approval. This article does not predict whether HF4142 will pass.

KFF (January 16, 2026) classifies Minnesota among the 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service as of January 2026. Minnesota is the 20th installment in this 50-state series and the 4th confirmed positive-coverage state (after NC, TN, and WI). It is the first state with a dedicated “Weight Management Agents” PDL class — a structural marker of institutional entrenchment — and simultaneously the positive-coverage state under the most active legislative threat as of May 2026.

Pattern #20 in the 50-state taxonomy: 4th positive-coverage state

The 20-pattern taxonomy built across this series places Minnesota in a structurally distinct position. Of the 19 prior states analyzed, 16 are some form of exclusion or termination state. Minnesota joins North Carolina (Pattern #9), Tennessee (Pattern #13), and Wisconsin (Pattern #19 — in flight) as the four confirmed positive-coverage states.

Minnesota’s pattern label is “Affirmative obesity-indication coverage with dedicated Weight Management Agents PDL class + active hostile exclusion legislation.” This pattern is unique in the taxonomy on two dimensions:

• Most institutionally entrenched positive-coverage state: a dedicated “Weight Management Agents” therapeutic PDL class signals that coverage is embedded in the formulary architecture itself, not merely listed under a broader hypoglycemic or specialty class. States that exclude weight-loss drugs do not need this class at all; its existence reflects an affirmative policy choice.
• Most legislatively threatened positive-coverage state: HF4142’s single-section exclusion — introduced March 9, 2026, laid over March 25, 2026 with possible omnibus inclusion — is the only active single-chamber hostile bill in the four positive-coverage states.

The four positive-coverage states ranked by institutional entrenchment vs. legislative threat:

Federal authority underpinning all four: 42 U.S.C. § 1396r-8(d)(2)(A) permits — but does not require — states to exclude “agents when used for anorexia, weight loss, or weight gain.” All four positive-coverage states have affirmatively chosen NOT to invoke this optional exclusion.

The dedicated “Weight Management Agents” PDL class

The Minnesota DHS Uniform PDL (effective January 1, 2025) contains a dedicated “Weight Management Agents” therapeutic class. Its document header reads verbatim:

“Minnesota Fee-for-Service and Managed Care Medicaid
Uniform Preferred Drug List effective: January 1, 2025”

The verbatim Weight Management Agents class (the canonical operative text):

“WEIGHT MANAGEMENT AGENTS section updated 12-1-2024
Preferred                                                    Nonpreferred
SAXENDA (SUBCUTANEOUS)                                 ORLISTAT (ORAL)
WEGOVY (SUBCUTANEOUS)                                  XENICAL (ORAL)
                                                                     ZEPBOUND (SUBCUTANEOUS)”

The “section updated 12-1-2024” notation indicates the Weight Management Agents class was most recently revised on December 1, 2024. The December 17, 2025 DHS Drug Formulary Committee meeting minutes confirm that no action was taken on Wegovy, Saxenda, Zepbound, or any drug in this class at that meeting. The most recent operative Weight Management Agents action remains the December 1, 2024 update.

Why a dedicated class matters structurally: Sixteen of the 19 prior states in this series with non-coverage or indication-anchored coverage have no Weight Management Agents PDL class at all — because a class whose entire purpose is chronic-weight-management coverage does not exist in their formularies. Minnesota’s dedicated class is a formal institutional marker that makes the coverage harder to dismantle than a class-deletion approach would require. To eliminate MN’s coverage legislatively, one must either delete the class from the PDL or — as HF4142 proposes — add a statutory exclusion that supersedes the PDL.

DHS Anti-Obesity Medications PA criteria (revised March 2023): verbatim

The operative prior-authorization document is the DHS Anti-Obesity Medications PA criteria page, last revised March 2023. The verbatim policy header:

“Anti-Obesity Medications
Drug — Anti-Obesity Medications
March 2023”

Covered drugs with PA

The verbatim covered-drugs list (the canonical drugs a prescriber may request under this criteria page):

“Covered drugs with prior authorization:
– Benzphetamine
– Contrave
– Diethylpropion or diethylpropion ER
– Lomaira
– Orlistat
– Phendimetrazine or phendimetrazine ER
– Phentermine capsules (Apidex-P and generics): 15mg, 30mg, 37.5mg
– Phentermine tablets (Apidex-P and generics): 37.5mg
– Saxenda
– Wegovy
– Xenical”

Critical gap: Zepbound (tirzepatide for chronic weight management) received FDA approval on November 8, 2023 — eight months after the March 2023 PA criteria page was last updated. Zepbound does NOT appear on the covered-drugs list above, yet it IS listed on the January 1, 2025 PDL Weight Management Agents class as Non-preferred with PA. Prescribers seeking Zepbound coverage should submit a PA request directly and confirm with the DHS Provider Help Desk how the criteria apply to this drug. The criteria likely apply by analogy under the “covered drugs with prior authorization” framework, but the formal text has not been updated.

Initial approval criteria (verbatim)

“Initial approval criteria for covered drugs with prior authorization:
– Patient must meet the age limit indicated in the FDA-approved label of the requested drug AND
– Documentation of initiation of or ongoing reduced calorie diet; OR
– Documentation of ongoing care of a registered dietitian nutritionist; AND
– Documentation of initiation of or ongoing regimen of increased physical activity unless medically contraindicated by co-morbidity AND
– Baseline body mass index (BMI) must be:
   Greater than or equal to 30 kg/m² with no risk factors (for patient at least 18 years of age) OR
   Greater than or equal to 27 kg/m² with at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia) (for patient at least 18 years of age) OR
   Greater than or equal to 30 kg/m² and body weight above 60 kg (for patient 12 to 17 years of age) AND
– Patient’s weight at baseline (in kg) must be submitted at time of request
– No contraindications (disease state or current therapy) should exist unless the prescriber documents that benefits outweigh risks AND
– No concurrent use of any other weight loss drug(s) AND
– Initial approval is for:
   6 months for Saxenda, Wegovy, Contrave, Xenical or orlistat; and may be renewed if renewal criteria is met. After lapses of therapy, additional trials may be approved if initial approval criteria is met.
   3 months for phentermine tablets and capsules, Lomaira, benzphetamine, diethylpropion or diethylpropion ER, phendimetrazine or phendimetrazine ER; and cannot be renewed. After lapses of therapy, additional trials may be approved if initial approval criteria is met.”

Renewal criteria (verbatim)

“Renewal criteria for covered drugs with prior authorization:
– Patient, at least 18 years of age, must have at least 5% weight loss during the initial approval period OR
– Patient, 12 to 17 years of age, must have at least 5% reduction in baseline BMI during the initial approval period AND
– Documentation of ongoing reduced calorie diet OR
– Documentation of ongoing care of a registered dietitian nutritionist AND
– Documentation of ongoing regimen of increased physical activity unless medically contraindicated by co-morbidity AND
– No contraindications (disease state or current therapy) should exist, unless prescriber documents that benefits outweigh risks AND
– Renewal approval is for 12 months
– Subsequent renewal approval (beyond 18 months) requires meeting all renewal criteria and documentation that patient maintains weight loss achieved during the initial approval period”

The quantity-limits provision (verbatim):

“Quantity limits
Quantity limits pursuant to the FDA-approved label will apply.”

Minnesota’s BMI thresholds are FDA-label-aligned: the BMI ≥ 27 with at least one weight-related comorbid condition threshold matches the Saxenda FDA label exactly. This is notably more permissive than Virginia’s BMI > 40 floor (the most restrictive in the series) and comparable to North Carolina’s criteria. The adolescent pathway (ages 12–17, BMI ≥ 30 + body weight > 60 kg) is consistent with FDA-approved adolescent indications for both Saxenda (approved for adolescents December 2020) and Wegovy (approved for adolescents December 2022).

Tirzepatide in two PDL classes: Mounjaro vs. Zepbound

Minnesota’s PDL architecture provides the clearest illustration in the 20-state cluster of the FDA-indication-anchored formulary principle: the same molecule — tirzepatide — appears in two distinct PDL classes anchored to two different FDA indications.

Claims for Mounjaro adjudicate against the T2DM-class PA criteria (diabetes-specific documentation). Claims for Zepbound adjudicate against the Anti-Obesity Medications PA criteria (BMI/lifestyle documentation). The two pathways are operationally separate; a patient with both T2D and obesity cannot use both simultaneously under the “no concurrent use of any other weight loss drug(s)” clause in the obesity PA criteria.

Similarly, semaglutide appears in two classes: Ozempic (semaglutide for T2DM) is Preferred in the Hypoglycemics class; Wegovy (semaglutide 2.4 mg for chronic weight management) is Preferred in the Weight Management Agents class. The verbatim Hypoglycemics class listing (updated 1-1-2025) includes Ozempic as Preferred and Rybelsus (oral semaglutide for T2DM) as Non-preferred — while neither semaglutide product appears on the Weight Management Agents class (Wegovy is listed by brand name, not by INN, which prevents cross-class confusion at the claims level).

The verbatim Hypoglycemics, Incretin Mimetics/Enhancers class (selected weight-management-relevant entries):

“HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS section updated 1-1-2025
Preferred: OZEMPIC (SUBCUTANE.) — VICTOZA (SUBCUTANE.) — BYETTA PENS (SUBCUTANE.) — BYDUREON BCISE (SUBCUTANE.) — SYMLIN PENS (SUBCUTANE.)
Non-preferred: MOUNJARO (SUBCUTANE.) — RYBELSUS (ORAL) — TRULICITY (SUBCUTANE.) — LIRAGLUTIDE (SUBCUTANE.) — XULTOPHY (SUBCUTANE.)”

Ozempic is Preferred for T2DM; Mounjaro is Non-preferred for T2DM; generic liraglutide (subcutaneous) is Non-preferred in the T2DM class while brand Saxenda (liraglutide 3 mg) is Preferred in the Weight Management Agents class — another illustration of the same-molecule, two-class principle.

HF4142: the active hostile exclusion bill

The Minnesota 94th Legislature (2026 session) has before it a single-section bill that would, if enacted, terminate weight-loss-indication coverage in Medical Assistance. The verbatim bill header:

“State of Minnesota
HOUSE OF REPRESENTATIVES
NINETY-FOURTH SESSION
H. F. No. 4142
03/09/2026
Authored by Nadeau, Gander and Rehrauer
The bill was read for the first time and referred to the Committee on Health Finance and Policy”

Verbatim short title:

“Medical assistance coverage of prescription drugs solely for weight loss prohibited.”

Verbatim bill summary:

“A bill for an act relating to human services; prohibiting medical assistance coverage of prescription drugs solely for weight loss; amending Minnesota Statutes 2025 Supplement, section 256B.0625, subdivision 13d.”

Verbatim operative amendment language

HF4142 would insert a new item (6) into the § 256B.0625 subd. 13d(b) exclusion list, renumbering the current item (6) (medical cannabis) to item (7). The verbatim new exclusion:

“(6) drugs or active pharmaceutical ingredients when used only for weight loss; and

(6) (7) medical cannabis flower as defined in section 342.01, subdivision 54, or medical cannabinoid products as defined in section 342.01, subdivision 52.”

Verbatim effective-date clause:

“EFFECTIVE DATE. This section is effective January 1, 2027, or upon federal approval, whichever is later.”

Structure and legislative status

HF4142’s status per the revisor.mn.gov case record (verified 2026-05-10):

“Short Title: Medical assistance coverage of prescription drugs solely for weight loss prohibited.
Authors: Nadeau, Gander, Rehrauer
Companion: None
Introduction Date: March 9, 2026
Committee Referrals: Health Finance and Policy (referred 03/09/2026)
Revisor Number: 26-07262”

The bill was laid over by the House Health Finance and Policy Committee on March 25, 2026 for possible inclusion in an omnibus health-finance vehicle. It was not voted on and was not killed. Minnesota’s omnibus mechanism allows policy provisions to migrate from individual bills into omnibus health-finance vehicles through the conference-committee phase; the 2026 session was scheduled to adjourn (~May 19, 2026).

Asymmetric bicameral sponsorship: HF4142 has three House sponsors (Nadeau, R-Rogers; Gander; Rehrauer) and no Senate companion. The Senate File numbered 4142 in the same biennium relates to climate financing, not human services. This structural asymmetry — House bill only, no Senate counterpart — is distinct from the hostile-legislation patterns in other states: NJ A3369 carries S2410; MD SB 0496 carries HB 0813; WA SB 5353 carries HB 1326. Minnesota’s HF4142 lacks bicameral sponsorship momentum as of May 10, 2026.

March 25, 2026 hearing testimony

The House Health Finance and Policy Committee hearing on March 25, 2026 produced the following verbatim fiscal-context testimony:

“Rep. Danny Nadeau, R-Rogers (bill sponsor): ‘My bill is not about a discussion whether or not obesity is a chronic disease and condition that needs to be treated. This is about balancing, or trying to balance, the costs of our health care system with the very, very increasing cost trend on certain drugs.’”

“Minnesota Budget Director Ahna Minge: ‘And what we’ve seen is from 2023 to 2024, a 90% increase, roughly, in the number of patients accessing those drugs through Medical Assistance.’”

“Fiscal estimate (Ahna Minge testimony): Drugs expected to increase Medical Assistance spending by $80 million to $90 million per biennium.”

Clinical opposition testimony:

“Dr. Claudia Fox, University of Minnesota: ‘I acknowledge that the costs of these medications are high, but the cost of untreated obesity will be higher.’”

“Dr. Aaron Kelly, University of Minnesota pediatrics professor: ‘Obesity is ground zero for countless other health consequences … High blood pressure, high cholesterol, Type 2 diabetes, heart disease and heart failure — very expensive diseases to manage — cancer, sleep apnea, osteoarthritis, kidney disease, liver disease, lower quality of life.’”

“Rep. Kristin Bahner (DFL-Maple Grove): The bill is ‘well-intentioned but short-sighted,’ essentially waiting ‘until you have a whole list of comorbidities’ rather than addressing obesity preventatively.”

The fiscal-pressure numbers from the hearing in summary form:

• 24% pharmaceutical-cost growth statewide in 2024 (Minnesota Council of Health Plans)
• 90% utilization growth in MA GLP-1 prescribing, 2023–2024 (Budget Director Minge)
• $12,000 per-patient annual cost by April 2025 (Minnesota Council of Health Plans)
• 12% of state pharmaceutical spend attributable to GLP-1 weight-loss drugs (Minnesota Council of Health Plans)
• $80–$90 million per biennium projected MA spending increase (Budget Director Minge)

Operative language analysis: HF4142’s phrase “when used only for weight loss” is indication-anchored, not drug-anchored. Even if enacted, HF4142 would NOT exclude GLP-1 drugs used for FDA-approved T2DM, MACE-reduction, MASH, or OSA indications — meaning Minnesota would likely transition to an indication-anchored coverage architecture (comparable to WA, OH, MD, NY) rather than full non-coverage (comparable to TX, FL, IL, GA). The carve-out for non-weight-loss indications is a structural consequence of the “when used only” qualifier.

This article does not predict whether HF4142 or any substantively similar omnibus language will be enacted. Readers should verify the bill’s current status at revisor.mn.gov before making any coverage assumptions.

UCare Minnesota Rehabilitation: out-of-Medicaid-scope context

On December 17, 2025 — the same day as the DHS Drug Formulary Committee quarterly meeting — UCare Minnesota was placed into Rehabilitation by order of the Ramsey County District Court, Second Judicial District. UCare is winding down operations under state regulatory supervision.

This event is documented here as a state-context structural fact that overlaps the HF4142 legislative timeline. It does NOT constitute a direct cause of HF4142’s introduction; the bill was introduced March 9, 2026, approximately eleven weeks after the Rehabilitation order. The fiscal arguments cited at the March 25, 2026 hearing (utilization growth, per-patient cost, pharmaceutical-spend share) were not linked by testifying officials to UCare’s specific insolvency.

Operational impact for affected members:

• Current and former UCare Medicaid members should consult the DHS annual health-plan-selection portal for guidance on transitioning to another MHCP MCO. The seven remaining MCOs are: Blue Plus (BCBS Minnesota), HealthPartners, Hennepin Health, Itasca Medical Care, Medica, PrimeWest Health, and South Country Health Alliance.
• PA approvals for Saxenda or Wegovy issued by UCare prior to the Rehabilitation order will NOT automatically transfer to a successor MCO. Members will likely need to resubmit PA documentation under the new MCO’s process.
• UCare’s formulary listed Saxenda and Wegovy as Preferred (PA required) and Zepbound as Non-preferred (PA required), consistent with the Uniform PDL. These entries are documented here for completeness but should not be treated as a current active coverage pathway.

UCare’s December 17, 2025 PDL was verified before the Rehabilitation order became operationally effective. The verbatim UCare PDL legend:

“P: Preferred; NP: Non-Preferred; CD: Covered Drug; AL: Limited to members of a certain age; DX2RX: Diagnosis Required; GE: Gender Limit; OTC: Over-the-Counter; PA: Prior Auth Required; QL: Quantity Limit; SP: Specialty Medication”

FFS-direct no-PBM architecture: the unique Minnesota MA administration model

Minnesota Medical Assistance fee-for-service pharmacy claims are administered directly by DHS through the MN-ITS (Minnesota Health Information Technology System) claims-adjudication infrastructure. There is NO contracted pharmacy benefit manager (PBM) intermediary in the FFS chain.

This is a structural distinction unique in the 20-state cluster (shared only with Wisconsin in Pattern #19). Comparing FFS administration across prior states:

For Minnesota FFS members, a denied PA claim routes through DHS directly with no PBM intermediary review layer. PDL changes flow from the Drug Formulary Committee recommendation to the DHS Commissioner to MN-ITS without requiring a PBM contract amendment.

The MCO population operates differently: each of the eight MHCP MCOs contracts its own PBM. Blue Plus (BCBS Minnesota) uses Prime Therapeutics, headquartered in Eagan, Minnesota — which is separately contracted as a Medicaid PBM in 28 states. Minnesota MA FFS does NOT use Prime Therapeutics; the in-state headquarters relationship does not create an administrative overlap. Medica uses Express Scripts for its MCO formulary adjudication.

Eight MHCP MCOs: pharmacy carve-out and uniform PDL alignment

Minnesota’s managed-care population is enrolled with eight local, nonprofit MCOs participating in the Prepaid Medical Assistance Program (PMAP, 1932(a)), MinnesotaCare (1115(a) waiver), Minnesota Senior Health Options (MSHO, 1915(a)/1915(c)), Minnesota Senior Care Plus (MSC+, 1915(b)/1915(c)), and Special Needs BasicCare (SNBC, 1915(a)):

1. Blue Plus (BCBS Minnesota) — PBM: Prime Therapeutics (Eagan, MN)
2. HealthPartners
3. Hennepin Health
4. Itasca Medical Care (county-based)
5. Medica — PBM: Express Scripts
6. PrimeWest Health
7. South Country Health Alliance (county-based)
8. UCare Minnesota — IN REHABILITATION as of December 17, 2025

All MCOs are required by DHS contract to align with the Uniform PDL for any class subject to uniform-PDL designation, including the Weight Management Agents class. MCOs may apply additional utilization-management criteria within FDA-approved indications, subject to DHS contract requirements. Verified MCO formulary data is available for Medica and UCare; formulary entries for Blue Plus, HealthPartners, Hennepin Health, Itasca Medical Care, PrimeWest Health, and South Country Health Alliance were not individually verified in this brief and should not be cited as individual sources.

The verbatim Medica 2025 MN Medicaid formulary entries illustrate MCO alignment with the Uniform PDL:

“SAXENDA SUBCUTANEOUS PEN INJECTOR 3 MG/0.5 ML (18 MG/3 ML) — Brand — PA; PDL-P; QL”

“WEGOVY SUBCUTANEOUS PEN INJECTOR 0.25 MG/0.5 ML, 0.5 MG/0.5 ML, 1 MG/0.5 ML, 1.7 MG/0.75 ML, 2.4 MG/0.75 ML — Brand — PA; PDL-P; QL”

“ZEPBOUND SUBCUTANEOUS PEN INJECTOR 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML — Brand — PA; PDL-NP; QL”

PDL-P = PDL Preferred; PDL-NP = PDL Non-preferred; PA = Prior Auth Required; QL = Quantity Limit. Medica’s entries exactly mirror the Uniform PDL Weight Management Agents classification.

T2D coverage is a separate PDL class

Minnesota MA covers GLP-1 receptor agonists for type 2 diabetes through the Hypoglycemics, Incretin Mimetics/Enhancers class — entirely separately from the Weight Management Agents class. These two coverage pathways are legally and operationally distinct:

• T2DM pathway: Ozempic (semaglutide for T2DM) is Preferred; Victoza (liraglutide for T2DM) is Preferred; Mounjaro (tirzepatide for T2DM) is Non-preferred; Trulicity (dulaglutide) is Non-preferred; Rybelsus (oral semaglutide for T2DM) is Non-preferred. PA criteria are diabetes-specific (HbA1c, diabetes diagnosis, etc.). T2DM coverage is NOT affected by HF4142 — the bill’s “when used only for weight loss” qualifier excludes the diabetes indication.
• Chronic weight management pathway: Saxenda and Wegovy are Preferred; Zepbound, Orlistat, and Xenical are Non-preferred. PA criteria are BMI/lifestyle-based (March 2023 criteria). This is the pathway HF4142 targets.

Patients with both T2D and obesity may have concurrent PAs — one for Ozempic under the T2DM class and one for Wegovy under the Weight Management class — but cannot use two GLP-1 drugs simultaneously under the “no concurrent use of any other weight loss drug(s)” clause. A patient on Ozempic for T2DM who also needs weight management should discuss with their prescriber whether Ozempic’s T2DM-indication dosing is sufficient or whether a therapy change is appropriate.

Comparison: how Minnesota sits among the 4 positive-coverage states

vs. North Carolina (Pattern #9 — double reversal)

NC is the counter-reversal state: covered August 2024 through September 2025, terminated 73 days, reinstated by gubernatorial directive December 12, 2025. NC now lists Wegovy as Preferred and Saxenda and Zepbound as Non-preferred in a dedicated Weight Management Agents class on the NC Medicaid PDL. NC’s coverage is also direct chronic-weight-management coverage (like MN), not indication-anchored. Differences: (a) NC’s dedicated class was added as an off-cycle change after termination and reinstatement; MN’s class predates the 2026 session by at least 15 months (updated 12-1-2024 per the PDL). (b) NC reinstated coverage by gubernatorial directive; MN’s coverage has never been terminated. (c) NC faces no active hostile bill as of May 10, 2026; MN has HF4142. (d) NC now uses Prime Therapeutics as a FFS PBM (effective May 2, 2026); MN FFS has no PBM intermediary.

vs. Tennessee (Pattern #13 — expansion from categorical exclusion)

TN was a categorical-exclusion state through July 31, 2025, then ADDED obesity-indication coverage effective August 1, 2025 via Sequence 10-34-25 emergency rulemaking (permanent effective January 26, 2026). TN lists both Wegovy and Zepbound as Preferred — the only state in the series where both Preferred-tier GLP-1s for weight management are co-listed. TN’s coverage is anchored in formal rulemaking (the most legislatively durable form after a statute). Minnesota’s coverage is anchored in PDL + statutory permissive framework; MN has a stronger statutory exclusion-bill threat (HF4142) than TN has. Fiscally: TN’s projected cost is $2.7M annually; MN’s is $80–$90M per biennium ($40–$45M annually) — a 15× larger fiscal exposure by state claims, likely reflecting population scale (Minnesota 1.3M MHCP vs. TennCare 1.8M but different eligibility structures).

vs. Wisconsin (Pattern #19 — positive with restrictive cap)

WI shares MN’s FFS-direct no-PBM architecture. Both states administer FFS pharmacy through DHS without a contracted PBM intermediary. Differences: WI imposes a 2-lifetime-attempts cap (members who have attempted GLP-1 obesity therapy twice lose access) and a BMI < 24 renewal-revocation clause (members who achieve BMI below 24 are removed from the covered class). MN’s PA criteria have no lifetime-cap provision and no BMI-ceiling renewal clause — once renewed, coverage continues as long as the 5%-weight-loss threshold is met. MN is substantively more patient-favorable than WI on these two dimensions.

The paradox: most entrenched but most threatened

Minnesota presents the starkest tension in the positive-coverage group: it has the most formally institutionalized coverage architecture (dedicated PDL class, no lifetime cap, no BMI ceiling, FDA-label-aligned thresholds) AND the most active legislative threat (single-chamber hostile bill, fiscal pressure of $80–$90M per biennium, 90% utilization growth). The dedicated PDL class makes the coverage harder to remove administratively (requires statutory override, as HF4142 proposes) but the fiscal scale of MN’s MA GLP-1 program makes it a high-priority budget target. Both facts are true simultaneously.

PA criteria gap: March 2023 text predates three new FDA indications

The DHS Anti-Obesity Medications PA criteria page was last revised March 2023. Three subsequent FDA approvals have not been incorporated into the published text as of May 10, 2026:

This is a documented gap, not an absence of coverage intent. The DHS PDL lists Zepbound as Non-preferred in the Weight Management Agents class (effective January 1, 2025), which post-dates the Zepbound FDA approval (November 8, 2023), indicating DHS took PDL action on Zepbound before updating the PA criteria text. Prescribers should contact the DHS Provider Help Desk to confirm the applicable PA criteria for Wegovy MASH, Wegovy MACE, and Zepbound OSA pathways before submitting requests under these indications. The March 2023 criteria page should not be cited as evidence that these newer indications are excluded; their status is unverified in this brief, not confirmed-excluded.

Minnesota in the 20-state taxonomy: where it fits

At 20 states, the taxonomy now covers the largest states by Medicaid enrollment plus a representative cross-section of geographic regions and coverage patterns. The distribution as of May 10, 2026:

• Affirmative positive coverage (4 states): NC, TN, WI, MN. Minnesota is the fourth and the one with the most active legislative threat.
• Conditional positive coverage (restrictive BMI floor) (1 state): VA (BMI > 40 floor).
• Indication-anchored coverage (non-obesity FDA indications only) (5 states): WA (MACE/MASH/OSA, explicit weight-loss exclusion); OH (Jan 2026 Metabolic Modifiers MACE/MASH carve-back-in); CA (MASH-only Wegovy reinstatement April 2026); MI (indication-anchored carve-outs via MDHHS Bulletin MSA 24-04); MD (HCPCS J3490 medical-benefit pathway for MACE/MASH, no retail pharmacy).
• Explicit non-coverage (7 states): TX, IL, NJ, NY, AZ, PA (terminated Jan 2026), MA (phase-out July 2026), IN.
• Silent operational exclusion (2 states): FL, GA.

Minnesota is the first state in the 20-state taxonomy where:

1. The state PDL has a dedicated “Weight Management Agents” therapeutic class with explicit Preferred/Non-preferred distinctions for the chronic-weight-management indication.
2. An active hostile exclusion bill with a specific effective date (January 1, 2027) targeting the weight-loss indication has been introduced in the current legislative session.
3. An MCO insolvency/rehabilitation event (UCare) overlaps the hostile-bill introduction in the same biennium.

Excluded populations and coverage boundaries

Patient action steps and appeal pathway

1. Verify MHCP enrollment. You must be an active Medical Assistance (MA) or MinnesotaCare member. CHIP (MinnesotaCare children’s coverage rules vary) and SEGIP (state employee plan) are separate programs.
2. Identify your coverage type. If you are FFS (no MCO), your pharmacy claims route directly through DHS via MN-ITS. If you are MCO-enrolled, contact your MCO for formulary details and PA submission instructions.
3. Confirm your BMI and comorbidity documentation. Adults 18+ need BMI ≥ 30 (no comorbidities required) OR BMI ≥ 27 with documented hypertension, T2DM, or dyslipidemia. Adolescents 12–17 need BMI ≥ 30 and body weight > 60 kg. Baseline weight in kg must be submitted with the PA request.
4. Document diet and physical activity engagement. The PA criteria require documentation of either an initiated reduced-calorie diet OR ongoing care of a registered dietitian nutritionist, AND initiated or ongoing physical activity regimen (unless medically contraindicated).
5. Request Saxenda or Wegovy (Preferred tier first). Zepbound is Non-preferred; accessing Zepbound requires documented failure or intolerance to a Preferred agent. The PA criteria do not specify a minimum trial duration for Preferred agents before Zepbound step.
6. For renewals: document 5% weight loss. The renewal threshold for adults 18+ is at least 5% weight loss during the initial 6-month approval period. Adolescents need 5% reduction in baseline BMI. Twelve-month renewals follow. Beyond 18 months, maintenance-of-weight-loss documentation is required.
7. If denied: file within 30 days. For FFS members, a state fair hearing request must be filed with the DHS Appeals Office within 30 days of the denial notice under MN Stat § 256.045. For MCO members, exhaust the MCO’s internal grievance/appeal process first, then escalate to a DHS state fair hearing.

Appeal pathway: DHS Appeals Division + State Fair Hearing

The Minnesota state fair hearing process is governed by MN Stat § 256.045. The verbatim appeal-process description:

“A State fair hearing request must be filed within 30 days after the MCO sends a notice for denial, termination, or reduction of services and within 90 days, if there is good cause for the delay pursuant to MN Statutes, Section 256.045.”

“When Minnesota Health Care Programs clients are not satisfied with county or state agency decisions, they or their authorized representatives may request that the DHS Appeals Office review the state or county agency actions or inactions.”

“The hearing is held either at a county office or by telephone. A DHS Human Services Judge conducts the hearing. The enrollee has the right to representation by a family member, friend, social worker, advocate, attorney or other interested party.”

Critical deadline: The 30-day window is among the shorter filing deadlines in the 20-state cluster (Texas allows 90 days; California allows 90 days; NJ allows 20 days). Missing the 30-day window without good cause may forfeit your right to an administrative hearing. Request continuation of benefits during the appeal at the time of filing — this preserves access while the DHS Appeals Office reviews the case.

PA approval is not guaranteed regardless of BMI or diagnosis. This article documents the published primary-source criteria as of May 10, 2026. Individual PA decisions depend on case-specific medical documentation and DHS or MCO clinical review. This article does not constitute medical or legal advice.

Related research

• North Carolina Medicaid GLP-1 coverage (2026): the double-reversal state — NC (Pattern #9) is the first positive-coverage state in the series. Like Minnesota, NC has a dedicated Weight Management Agents PDL class with Wegovy Preferred. Unlike Minnesota, NC completed an on-off-on cycle within 73 days in 2025–2026 and reinstated coverage by gubernatorial directive. NC faces no active hostile bill as of May 10, 2026; Minnesota faces HF4142.
• Tennessee Medicaid GLP-1 coverage (2026): expansion from categorical exclusion — TN (Pattern #13) added obesity-indication coverage August 1, 2025 via formal rulemaking. TN has both Wegovy and Zepbound as Preferred — the broadest AOM panel in the series. Among the four positive-coverage states ranked by legislative threat, TN is the most secure (rulemaking anchor, no active hostile bill), NC is reinstated-by-directive, WI is positive with a restrictive cap, and MN is the most institutionally entrenched but most legislatively threatened.
• GLP-1 pricing index: real telehealth costs, Wegovy cash pay, Zepbound coupons — Minnesota is a positive-coverage state with an active hostile bill creating near-term uncertainty. If HF4142 or similar omnibus language is enacted effective January 1, 2027, Minnesota members who currently access Saxenda or Wegovy through MA would need to evaluate cash-pay telehealth pricing. The pricing index documents the current cost structure for uninsured and out-of-pocket pathways.
• GLP-1 insurance-dropped coverage appeal playbook — If HF4142 passes and MN terminates weight-loss GLP-1 coverage January 1, 2027, members will face the same coverage-loss scenario documented in this appeal playbook. The four-phase appeal structure (internal MCO appeal → DHS state fair hearing → federal complaint → civil litigation) applies to Minnesota’s § 256.045 framework.
• Pennsylvania Medicaid GLP-1 coverage (2026): the policy reversal — PA (Pattern #7) terminated 34 months of obesity coverage effective January 1, 2026. Minnesota’s current fiscal pressure ($80–$90M per biennium, 90% utilization growth) closely mirrors the fiscal arguments PA used to justify termination. The article does not predict Minnesota will follow PA’s path, but the structural similarity is documented.

Sources and last verified date

Last verified: 2026-05-10. All primary sources were accessed by direct document retrieval on this date. The MN DHS Anti-Obesity Medications PA criteria web page (revised March 2023) was confirmed intact and unmodified as of 2026-05-10. The January 1, 2025 Uniform PDL PDF was confirmed accessible. HF4142 bill status was confirmed at revisor.mn.gov as of 2026-05-10. Readers should verify PDL, PA criteria, and HF4142 status directly before making coverage decisions.